
Description |
DHEA is an important source of androgens, and is an effective antiapoptotic factor. |
---|---|
IC50 & Target |
Androgen receptor[1] |
In Vitro |
DHEA is an effective antiapoptotic factor, reversing the serum deprivation-induced apoptosis in prostate cancer cells (DU145 and LNCaP cell lines) as well as in colon cancer cells (Caco2 cell line). DHEA significantly reduces serum deprivation-induced apoptosis in all 3 cancer cell types, quantitated with the APOPercentage assay (apoptosis is reduced from 0.587±0.053 to 0.142±0.0016 or 0.059±0.002 after treatment for 12 hours with DHEA or NGF, respectively; n=3, P<0.01), and="" by="" flow="" cytometry="" analysis="" (facs)="" for="" du145="" cells.="" the="" antiapoptotic="" effect="" of="" dhea="" is="" dose="" dependent="" with="" an="" ec50="" at="" nanomolar="" concentrations="">0.01),>50: 11.2±3.6 nM and 12.4±2.2 nM in DU145 and Caco2 cells, respectively)[1]. DHEA is the principal sex steroid precursor in humans and can be converted directly to androgens. DHEA (≥1 μM) causes a dose-dependent inhibition of Chub-S7 proliferation, as assessed by thymidine incorporation assays. DHEA treatment inhibits expression of the key glucocorticoid-regulating genes H6PDH (≥100 nM) and HSD11B1 (≥1 μM) in differentiating preadipocytes in a dose-dependent manner. In keeping with this finding, DHEA treatment (≥1 μM) results in a marked reduction in 11β-HSD1 oxoreductase activity (≥1 μM) and a concurrent increase in dehydrogenase activity at the highest DHEA dose used (25 μM DHEA) in differentiated adipocytes[2]. |
In Vivo |
DHEA in the diet (0.45 % w/w) of male B6 mice (groups of five mice) treated for 8 weeks led to significant decreases in body temperature compared with mice fed the control AIN-76A diet. A similar comparison indicated that control and pair-fed mice are also significantly different. Animals fed DHEA have significantly lower temperatures than mice fed the control diet 26/29 times tested; mice pair fed to those on the DHEA diet are less affected, with 8/29 values significantly lower than in mice fed AIN-76A ad libitum. The temperatures of mice fed DHEA or pair fed to DHEA are significantly different 21/29 times tested. Body weights are significantly greater in mice fed the control diet than in mice fed DHEA or pair fed to DHEA. Food intake (grams per day) from cages are averaged for each week (n=7), except for Week 9 (n=3). The amount of food intake is significantly decreased in mice fed DHEA. By design, mice pair fed to DHEA ate about the same amount. Thus, it appears that DHEA reduces body temperature by food restriction and by a separate mechanism[3]. |
References |
|
Preparing Stock Solutions |
Please refer to the solubility information to select the appropriate solvent.
|
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Kinase Assay
[2] |
Chub-S7 cells are incubated in DMEM containing cold DHEA (20 nM) and tritiated DHEA (0.2 μCi/well) for 48 h. Following incubation, steroids are extracted using dichloromethane separated by thin-layer chromatography using n-hexane/1-hexanol (75:25) as the mobile phase system. Metabolites are identified by comigration with unlabeled reference steroids that are visualized by exposure to Lieberman-Burchard reagent (ethanol-acetic anhydride-sulfuric acid). Steroid conversion is quantified using a LabLogic AR-200 scanner. Protein concentration is measured using a colorimetric 96-well plate assay and used to normalize conversion. Activity is expressed as percent conversion[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
Cell Assay
[2] |
DHEA is dissolved in DMSO and stored, and then diluted with appropriate medium before use[2]. Chub-S7 preadipocytes and human primary preadipocytes are seeded into a 24-well plate at densities 1×105 and 2.5×105 respectively. Following overnight culture, medium is supplemented with DHEA, androstenediol, or DHEAS (0-100 μM). Following 24-, 48-, or 72 h incubation, cell proliferation is assessed by incubation with radiolabeled thymidine (0.2 μCi/well) for the final 6 h of culture. Proteins are precipitated with TCA, and cells are scraped in NaOH. The respective content of radiolabeled nuclear material in the resulting lysates is analyzed by scintillation counting. Data are expressed as percentage of control[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
Animal Administration
[3] |
DHEA is prepared in 0.9% NaCl (Mice)[3]. Mice[3]
|
||||||||||||||||
References |
|
Molecular Weight |
288.42 |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Formula |
C₁₉H₂₈O₂ |
||||||||||||
CAS No. |
53-43-0 |
||||||||||||
Storage |
|
||||||||||||
Shipping | Room temperature in continental US; may vary elsewhere |
||||||||||||
Solvent & Solubility |
10 mM in DMSO
* "<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">1> |
Purity: >98.0%
COA (94 KB) HNMR (176 KB)
Handling Instructions (1252 KB)-
[1]. Anagnostopoulou V, et al. Differential effects of dehydroepiandrosterone and testosterone in prostate and colon cancer cell apoptosis: the role of nerve growth factor (NGF) receptors. Endocrinology. 2013 Jul;154(7):2446-56.
[2]. McNelis JC, et al. Dehydroepiandrosterone exerts anti-glucocorticoid action on human preadipocyte proliferation, differentiation and glucose uptake. Am J Physiol Endocrinol Metab. 2013 Nov 1;305(9):E1134-44.
[3]. Catalina F, et al. Decrease of core body temperature in mice by dehydroepiandrosterone. Exp Biol Med (Maywood). 2002 Jun;227(6):382-8.
ebiomall.com






>
>
>
>
>
>
>
>
>
>
>
>
求助大家,小分子药物最新专利申请情况跟踪,之前听别人说可以在一个网站可以导出这个信息。
不知哪位大侠知道,告知一下,不胜感激!
有机的是有机化合物的简称,它指的是含碳化合物.
但是,有四大类常见物质一般不作为有机物处理:
1、碳的氧化物,如CO和CO2.
2、碳酸及其盐,如CaCO3.
3、金属碳化物,如CaC2.
4、拟卤素及其化合物,如(CN)2与KSCN.
水的化学式为H2O,它不含有碳元素,故不是有机物.
但若所描述的水不是化学意义的水,而是自然界存在的天然水,那么,水中会溶有一定量的有机物.
2017年4月26日|Filedunder:制药工业,制药企业,孤儿药,新药研发,制药常识,文献综合|Postedby:路人丙
【新闻事件】:在日前正在举行的美国神经学年会上MitsubishiTanabe公布了其ALS药物Edaravone的一个三期临床试验结果。在标准疗法基础上加入Edaravone显著改善ALS患者综合功能指标ALSFRS-R(-5.0对-7.5),同时也改善运动、呼吸等局部功能。Edaravone已经在韩国日本批准用于ALS,去年10月申请在美国上市,今年6月之前有望批准。
【药源解析】:ALS全称叫“肌肉萎缩性侧面硬化病”,也称LouGehrig氏病,因为30年代美国纽约洋基棒球队著名选手LouGehrig死于这个病。2014年风行一时的冰桶挑战让更多人知道了ALS,但ALS新药发现依然缓慢。美国目前只有riluzole这一个上市药物,能增加~10%的一年生存机会。
ALS的发病机理未知,动物模型十分不可靠,所以这个病的新药开发很难。过去10年大约只有十几个药物进入临床,基本全军覆没。走的最远的是百建艾迪的dexpramipexole,2013年初在三期临床失败。Edaravone号称是游离基清除剂,但分子机理未知。Edaravone最早作为中风药物开发,后来扩展到ALS。第一个三期临床失败,今天公布的是症状较轻患者。这个临床是日本人群,Edaravone并没有在美国IND和开展临床试验,所以如果批准将是比较特殊的情况(和Marathon的DMD药物Emflaza情况类似)。
Edaravone的另一个特殊性质是其分子结构。这个化合物分子十分简单,分子量只有174,可以算作是超小分子药物。现在有几十个分子量小于200的FDA批准药物,这类药物因为官能团数目有限不大可能与任何靶点有较高结合能,所以通常靶点未知。靶点未知又没有可靠动物模型,这类药物发现就更加困难。当然动物模型预测性差不是超小分子药物才面临的难题,多数神经系统药物、甚至现在最火热的肿瘤免疫疗法也面临同样问题。
这种临床前缺乏可靠评价体系的药物可以算是有D无R,这要求厂家冒更大的临床风险。只有潜在回报较大如没有任何标准疗法的罕见病或真正颠覆性药物如免疫疗法才可以适当采用这个模式。这个模式扩大化对厂家的长期生存是个威胁,因为新药的未知因素已经很多、成功率已经很低。没有临床前适当去风险的机会主义不可持续。
转发分享
美中药源原创文章,转载注明出处并添加超链接,商业用途需经书面授权。
★更多深度解析访问《美中药源》~
https://www.yypharm.com/?p=10664
求助各位大神,现在想购买小分子数据库,求大神推荐。
我知道的免费的数据库有zinc
求推荐哪家公司或者研究所的小分子数据库可以购买,十分感谢!!!!!!
如题,之前没做过药代,老师给了一个600+Da的五肽,想测下药代动参数,看文献推荐上述两种方法,但是不知道选哪种更好,lcms前处理会不会影响小肽。

